Insmed Incorporated (LON:0JAV)

Insmed Statistics

Total Valuation

Insmed has a market cap or net worth of GBP 22.40 billion. The enterprise value is 21.58 billion.

Market Cap	22.40B
Enterprise Value	21.58B

Important Dates

The next estimated earnings date is Thursday, October 30, 2025.

Earnings Date	Oct 30, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	211.37M
Shares Outstanding	n/a
Shares Change (YoY)	+22.38%
Shares Change (QoQ)	+4.67%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	190.47M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	77.09
PB Ratio	24.56
P/TBV Ratio	28.34
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-28.59
EV / Sales	74.06
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-34.04

Financial Position

The company has a current ratio of 6.68, with a Debt / Equity ratio of 0.59.

Current Ratio	6.68
Quick Ratio	6.13
Debt / Equity	0.59
Debt / EBITDA	n/a
Debt / FCF	-0.85
Interest Coverage	-10.49

Financial Efficiency

Return on equity (ROE) is -160.54% and return on invested capital (ROIC) is -34.07%.

Return on Equity (ROE)	-160.54%
Return on Assets (ROA)	-27.03%
Return on Invested Capital (ROIC)	-34.07%
Return on Capital Employed (ROCE)	-42.79%
Revenue Per Employee	228,621
Profits Per Employee	-593,993
Employee Count	1,271
Asset Turnover	0.19
Inventory Turnover	0.98

Taxes

In the past 12 months, Insmed has paid 3.24 million in taxes.

Income Tax	3.24M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +97.10% in the last 52 weeks. The beta is 0.97, so Insmed's price volatility has been similar to the market average.

Beta (5Y)	0.97
52-Week Price Change	+97.10%
50-Day Moving Average	121.14
200-Day Moving Average	87.69
Relative Strength Index (RSI)	67.93
Average Volume (20 Days)	5,903

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.24

Income Statement

In the last 12 months, Insmed had revenue of GBP 290.58 million and -754.97 million in losses. Loss per share was -4.18.

Revenue	290.58M
Gross Profit	220.01M
Operating Income	-677.11M
Pretax Income	-751.73M
Net Income	-754.97M
EBITDA	-669.65M
EBIT	-677.11M
Loss Per Share	-4.18

Balance Sheet

The company has 1.36 billion in cash and 539.43 million in debt, giving a net cash position of 815.83 million.

Cash & Cash Equivalents	1.36B
Total Debt	539.43M
Net Cash	815.83M
Net Cash Per Share	n/a
Equity (Book Value)	912.18M
Book Value Per Share	4.32
Working Capital	1.29B

Cash Flow

In the last 12 months, operating cash flow was -616.44 million and capital expenditures -17.53 million, giving a free cash flow of -633.97 million.

Operating Cash Flow	-616.44M
Capital Expenditures	-17.53M
Free Cash Flow	-633.97M
FCF Per Share	n/a

Margins

Gross margin is 75.72%, with operating and profit margins of -233.02% and -259.82%.

Gross Margin	75.72%
Operating Margin	-233.02%
Pretax Margin	-258.70%
Profit Margin	-259.82%
EBITDA Margin	-230.46%
EBIT Margin	-233.02%
FCF Margin	n/a

Dividends & Yields

Insmed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.38%
Shareholder Yield	n/a
Earnings Yield	-3.37%
FCF Yield	-2.83%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Insmed has an Altman Z-Score of 3.44 and a Piotroski F-Score of 3.

Altman Z-Score	3.44
Piotroski F-Score	3